-
Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines
NEW YORK, July 31, 2025 -- Eviva Partners, a nonprofit organization dedicated to strengthening public understanding of medical evidence, is proud to announce the launch of Protecting Our Health (POH), a new think tank that brings together international experts in communication, public health and misinformation to confront the rise of pseudoscience. "Medical research has generated a tremendous number of evidence-based interventions, but these are not universally adopted, leading to gaps in care," said Eviva CEO and founder Alex Morozov, a physician-scientist, writer and former
- 김갑성 기자
- 2025-07-31 02:42
-
Egg Medical Announces U.S. Patent and Trademark Office Issues Final Rejection of All Claims in Rampart IC's Radiation Shield Patent Following a Reexamination Challenge
ST. PAUL, Minn., July 30, 2025 -- In a significant development in an ongoing legal dispute, the U.S. Patent and Trademark Office (USPTO) has issued a final rejection of all claims in U.S. Patent No. 11,660,056 held by Rampart IC, LLC related to a radiation shielding device. The decision follows a request for reexamination by Egg Medical, Inc., which argued that Rampart's '056 patent covered technology that had already been invented—some examples dating as far back as the 1960s. Egg Medical's reexamination request arose out of a lawsuit that Rampart filed in federal cour
- 김갑성 기자
- 2025-07-30 22:24
-
BON Launches AI-Powered New Drug Research and Development
XI'AN, China, July 30, 2025 -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D) business. Leveraging its extensive library of natural compounds - many derived from Traditional Chinese Medicine (TCM) - the Company will apply artificial intelligence algorithms to identify high potential lead compounds, marking a significant evolution in its pharmaceutical strategy.
- 김갑성 기자
- 2025-07-30 21:00
-
Emerald Clinical Trials Confirms CEO Transition and Continuity Plan
SINGAPORE, July 30, 2025 -- Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition. Mary Gunn has stepped down effective immediately. The Board has appointed Glenn Kerkhof, a long-standing Board member and experienced CRO executive, as Interim CEO. The Board has commenced a formal search for a permanent CEO and has asked Glenn Kerkhof to lead the organization through this period to ensure continuity, stability and strong execution. "We thank Mary for her contributions," said Sean Carney, Chair of the Bo
- 김갑성 기자
- 2025-07-30 20:00
-
Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company
[ 메디채널 김갑성 기자 ] - First global out-licensing deal since founding — tangible return on new drug development investments - Significant milestone payments and future revenue expected — additional out-licensing of proprietary technologies anticipated SEOUL, South Korea, July 30, 2025 -- Dx&Vx (DXVX) has signed its first-ever global out-licensing agreement since its establishment. On July 30, DXVX announced that it has entered into a co-development and license agreement valued at approximately USD 220 million with a U.S.-based biotech company for its mRNA-based cancer va
- 김갑성 기자
- 2025-07-30 20:00
-
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS
Key Takeaways Participating in the Supplemental Nutrition Assistance Program (SNAP) may help protect against age-related cognitive decline, suggests an analysis of a national study. Compared to non-participants, SNAP participants had a slower decline in cognitive function during the 10-year study period, effectively maintaining an average of two to three additional years of cognitive health. Food insecurity can negatively impact cognitive function, and participating in SNAP may improve participants' diets and nutrition intake. TORONTO, July 30, 2025 -- People w
- 김갑성 기자
- 2025-07-30 19:00
-
레오 캔서 케어, 혁신적인 직립형 방사선 치료 플랫폼 마리(Marie®)로 FDA 510(k) 허가 획득
미들턴, 위스콘신주, 2025년 7월 30일 -- 직립형 방사선 치료 솔루션 분야 선도 기업 레오 캔서 케어(Leo Cancer Care)가 29일 자사의 주력 제품인 마리의 미국 식품의약국(FDA) 510(k) 허가 획득을 발표했다. 마리는 입자 치료 전달 방식의 패러다임을 전환하는 플랫폼으로, 환자의 직립 자세 유지 시스템과 CT 스캐너를 결합해 환자와 의료진 모두에게 새로운 치료 경험을 제공하며, 기존 입자 치료 솔루션에 비해 장비의 크기와 비용을 획기적으로 줄였다. 스티븐 토우(Stephen Towe) 레오 캔서 케어 최고경영자(CEO)는 "이번 허가는 레오 캔서 케어뿐만 아니라 암 치료의 미래에 있어서도 중요한 이정표가 될 것"이라고 말했다. 그는 이어 "우리는 오랫동안 방사선 치료를 보다 인간적인 방식으로 제공할 수 있다고 믿어왔다. 환자를 치료의 중심에 두고 보다 스마트하면서도 배려 깊게 적용하는 것으로, 마리는 그 믿음을 담아낸 결과물"이라고 덧붙였다. 양성자 치료와 탄소 이온 치료 같은 입자 치료는 오랫동안 방사선 종양학 분야에서 표준 치료
- 김갑성 기자
- 2025-07-30 15:54
-
Ping An Ranks 47th on 2025 Fortune Global 500 List, Marking 16th Year on List
HONG KONG and SHANGHAI, July 30, 2025 -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) is #47 globally on the latest Fortune Global 500 list, up six places from 2024, with operating revenue of about USD158.63 billion. The Company, which ranked 9th among global financial enterprises, has been included in the Fortune Global 500 list for 16 consecutive years. Ping An continues to advance its technology-enabled "integrated finance + health and senior care" strategy, accelerating it
- 황정호 기자
- 2025-07-30 15:17
-
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 30, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present Phase II clinical data on its next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), at the ESMO Congress 2025, taking place October 17-21, 2025, in Berlin, Germ
- 김갑성 기자
- 2025-07-30 08:01
-
Telix H1 2025 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025. An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025). Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/x4gytx8w/ Participants can register for the teleconference here: ht
- 황정호 기자
- 2025-07-30 07:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-31_SUN
2025-08-30_SAT
- Global Trade Review Announces GTR Asia 2025 in Singapore - the premier platform for the trade community in the Asia Pacific region - hits over 1,500 registration for September 2-3 23:39
- SENGKANG GENERAL HOSPITAL HOLDS MEN'S HEALTH FORUM TO CHAMPION PREVENTIVE CARE AND WELLBEING AMONG MEN IN SINGAPORE 21:33
- 成長への入り口：第8回CIIEにおけるイノベーションと機会 20:57
- 성장의 관문: 제8회 CIIE의 혁신과 기회 20:44
- 제이씨바이오•MGI 테크, 한국 내 멀티오믹스 혁신 촉진 위한 DCS 연구소 프로젝트 협력 발표 15:37
- Global Launch of AEROVENT ZERO: China-Developed Innovation Ushering Tech Textiles into a PFAS-Free Era 15:16
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 31일 05시 20분